J B Chemicals &
Drug Manufacturers - Specialty & Generic · JBCHEPHARM
Large CapHealthcareHigh Growth
Nikhil Chopra
CEO and Whole-Time Director · Transformational
Company DNA
Performance-Driven
About
J B Chemicals & is a Large Cap company in the Healthcare sector, listed on NSE as JBCHEPHARM. With a market cap of ₹33K Cr and revenue of ₹4K Cr, it is currently in the High Growth phase. Known for its Performance-Driven culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Focused on specialty and generic drug segments with a professional management team prioritizing market share and bottom-line efficiency. Its strategic mandate: Requires aggressive geographic and therapeutic segment scaling to capitalize on current domestic market momentum and expand its branded generics footprint.
FAQ
What kind of company is J B Chemicals &?
J B Chemicals & is a Large Cap Healthcare company (JBCHEPHARM) in the High Growth phase with a market cap of ₹33K Cr. It is classified as Performance-Driven in culture.
What is J B Chemicals &'s culture and work environment like?
J B Chemicals & has a Performance-Driven culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Focused on specialty and generic drug segments with a professional management team prioritizing market share and bottom-line efficiency.
Who leads J B Chemicals &?
J B Chemicals & is led by Nikhil Chopra (CEO and Whole-Time Director), a Transformational leader with 29 years of experience.
What are J B Chemicals &'s financials?
J B Chemicals & reported revenue of ₹4K Cr in FY25 with a 5-year revenue CAGR of 16.8%. Operating margin: 22.1%. Market cap: ₹33K Cr.
Culture & Strategy
CulturePerformance-Driven
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTrusted
LifecycleHigh Growth
Focused on specialty and generic drug segments with a professional management team prioritizing market share and bottom-line efficiency.
Mandate
Requires aggressive geographic and therapeutic segment scaling to capitalize on current domestic market momentum and expand its branded generics footprint.
Requires aggressive geographic and therapeutic segment scaling to capitalize on current domestic market momentum and expand its branded generics footprint.
Financials
Revenue FY25₹4K Cr
PAT FY25₹660 Cr
Rev CAGR 5Y16.8%
OPM22.1%
NPM17.1%
ROE19.2%
ROCE23.5%
P/E44.6
Fwd P/E35.4
P/B8.7
D/E1.1
Mkt Cap₹33K Cr
Promoter49.2%
Institutional28.4%
Similar Culture
Could You Lead J B Chemicals &?
Take the Genome Benchmark →